A novel complement therapeutic CTx001 offers a novel approach to treating geographic atrophy. Complement Therapeutics (CTx) is a Germany-based preclinical stage biotechnology company focusing on the R ...

Beam Therapeutics Inc (NASDAQ: BEAM) joins forces with Apellis Pharmaceuticals Inc (NASDAQ: APLS) to create new gene-editing treatments for complement-driven diseases. The partnership will leverage ...

Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...

Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported interim data from Part 1 of an ongoing phase 1/2 trial of ARO-C3 in healthy people as a potential therapy for complement mediated diseases. The ...

REDWOOD CITY, Calif. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Kriya Therapeutics, Inc., a fully integrated company pioneering novel technologies and therapeutics in gene therapy, today ...

Round led by Gimv, a Belgian based private equity and venture capital firm Round comes just 1 year after raising €5 million seed funding in February 2022 Company aims to transform the treatment of ...

Also called C3G, this rare kidney disease often affects children and young adults, but it can happen at any age. It has a major impact on a person’s health and life. C3G has two forms: dense deposit ...

The "Dense Deposit Disease Market - A Global and Regional Analysis: Focus on Drug Class, Route of Administration, and Region - Analysis and Forecast, 2025-2035" has been added to ...

A preclinical biotechnology company, spun out of The University of Manchester, has announced the completion of a €72 million finance deal to develop the treatment of a leading cause of blindness. The ...